Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Learn how Zero-Knowledge Proofs (ZKP) provide verifiable tool execution for Model Context Protocol (MCP) in a post-quantum world. Secure your AI infrastructure today.

Thank you to everyone who hosted watch parties and celebrated National Chemistry Week 2025 with us! If you were unable to attend live, ACS invites you to use the recording of this year's event ...